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Preventing neural tube defects in Europe: population
based study
Araceli Busby, Lenore Abramsky, Helen Dolk, Ben Armstrong, a Eurocat Folic Acid Working Group
Each year, more than 4500 pregnancies in the
European Union are affected by neural tube defects.
Unambiguous evidence of the effectiveness of pericon-
ceptional folic acid in preventing neural tube defects
has been available since 1991,1 and improving folate
status sufficiently could result in the prevention of
more than two thirds of all neural tube defects. We
report on trends in the prevalence of neural tube
defects up to 2001, in the context of a survey in 16
European countries of periconceptional folic acid
policies and their implementation.2 3
Participants, methods, and results
Eurocat is a network of population based congenital
anomaly registries in Europe (www.eurocat.ulster.
ac.uk). A total of 9 273 212 births were surveyed by 31
registries in 16 countries 1980-2001,3 including 8913
babies or fetuses with neural tube defects (anen-
cephaly, spina bifida, or encephalocele): 3298 live
births, 844 stillbirths, and 4771 terminations of
pregnancy after prenatal diagnosis. In the United
Kingdom and Ireland, yearly prevalence of neural tube
defects declined, predating any periconceptional folic
acid supplementation policy initiatives, from 45 per
10 000 births in 1980 to 10 to 15 per 10 000 in the
1990s (figure). In contrast, in the rest of Europe the
prevalence during the 1980s and thereafter was close
to 10 per 10 000 births (figure).
The first governments to formulate a periconcep-
tional folic acid supplementation policy were the
United Kingdom (1992), Ireland (1993), and the Neth-
erlands (1993); six more (Switzerland 1996, Denmark
1997, Norway 1998, Portugal 1998, France 2000, and
Spain 2001) followed. Malta (1994) and Finland (1995)
recommended raising folate status by dietary means
only. Austria, Belgium, Croatia, Germany, and Italy had
no government policy, although in all these countries
professional bodies have issued guidelines or
recommendations.2
For 23 of the registers with data going back to at
least 1990, we compared changes in prevalence over
time according to policy type by estimating, for each
registry, the ratio of prevalence in 1999-2001 to
1989-91 and calculating the mean of such ratios (on a
log scale) for all registries in countries with similar
policy types (as introduced by 1999), using standard
random effects meta-analysis techniques.3 In the
United Kingdom and Ireland we found a significant
overall mean reduction in the prevalence of neural
tube defects in 1999-2001 compared with 1989-1991
(32% (17% to 44%)), continuing a trend that preceded
policies of folic acid supplementation. Registries in
other countries with a policy of raising periconcep-
tional folate status (by supplementation or dietary
means) introduced by 1999 had a mean reduction in
prevalence of 17% (44% reduction to 4% increase),
whereas registries from countries with no policy by
1999 showed a mean reduction of 9% (26% reduction
to 12% increase).3
Comment
The prevalence of neural tube defects in Europe has
not declined substantially in the past decade despite
national policies of folic acid supplementation in half
the countries. The prevalence in the United Kingdom
and Ireland fell by 32% continuing a stronger
pre-existing trend and remains slightly higher than
overall European levels. These data suggest that
policies simply recommending periconceptional sup-
plementation of folic acid in planned pregnancies are
not effective enough. Many women may not receive or
respond to health promotion messages stressing the
need to commence supplementation preconception-
ally, or may remain unaware that dietary modifications
are unlikely to achieve sufficient folate intake,w1 and a
large proportion of pregnancies in most countries are
unplanned.2 Folate status of most women of
childbearing age could be raised by fortifying a staple
food with folic acid,4–5 which would also help to reduce
socioeconomic inequalities in the prevalence of neural
tube defects. Health effects of supplementation and
fortification should be monitored, and policies
should be reviewed periodically in light of the
findings. The potential for preventing neural tube
defects in Europe by raising folate status is still far
from being fulfilled,1 and it is unacceptable to
continue to rely mainly on prenatal screening and ter-
mination to reduce the number of babies born with
neural tube defects.2 w2
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Information about the figure and references w1 and w2 are on
bmj.com
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What is already known on this topic
Periconceptional folic acid supplementation can
prevent most neural tube defects if widely used
Supplementation must begin before conception
for it to be effective
What this study adds
Lack of a substantial decline in neural tube defect
prevalence in Europe since 1991 shows that the
potential for preventing neural tube defects is still
far from being fulfilled
Periconceptional supplementation and
fortification of staple foods is needed to reach all
women before conception and to prevent
widening of socioeconomic inequalities
The mystery of the milky effusion
A 59 year old man was admitted to our cardiac surgical intensive
care unit after a third operation on the mitral and aortic valves.
His previous operations had been six months before. All three
surgeries were done via a median sternotomy, and the left pleural
space was never opened during the operations.
The postoperative recovery was initially uneventful. The day
after surgery the patient was extubated, and the chest drains
removed. The next day, however, we noticed a reduced air entry
in the left lower zone of the chest, and a chest x ray showed some
haziness in the left lower zone, consistent with a collection of fluid
in the left pleural space. A diagnostic aspiration with a 14 gauge
venous cannula in the seventh intercostal space in anterior
axillary line produced a whitish fluid that looked uncannily like
fresh milk.
Laboratory tests confirmed that the fluid was chyle, and the
absence of vegetable particles ruled out stomach contents.
Chylothorax due to excessive sternal retraction causing injury to
the thoracic duct, though rare, is not unknown. The lab
categorically labelled the aspirate as chyle and not as milk from
the stomach. However, a vigilant attending nurse noted that the
patient had drunk 250 ml of milk only 30 minutes before the
aspiration. Meanwhile, the sample in the kidney tray showed
curdling after two hours.
Because of persistent haziness on the chest x ray, we took a
second aspirate at the sixth intercostal space the next day. This
produced serosanguinous fluid rather then chyle, and we inserted
an intercostal drain, which drained 600 ml in the first 24 hours.
We removed the drain after 48 hours and ruefully concluded that
the “chyle” of the first sample must have been due to
transthoracic stomach aspiration.
We had all got carried away by the milky aspirate and had
considered the exotic possibility of chylothorax from repeat
surgeries and extensive retraction of the sternum. Even in a busy
cardiac surgical intensive care unit that treats some 1200-1300
cases of open heart surgery a year, a simple situation can be
made complex by incorrect interpretation of laboratory results.
The milk didn’t curdle in the patient’s stomach immediately
because of the high pH of his gastric juice after routine use of H2
blockers. The pathologist didn’t see any vegetable matter in the
sample, but the patient had taken only clear fluids for the
previous 24 hours. Aspiration was done with the patient in a
semi-recumbent position (because of his postoperative status),
with a full stomach (250 ml of milk), and during expiration.
Clearly, the needle went through the chest wall, pleural space,
diaphragm, and peritoneal space and reached the stomach.
Some lessons can be learnt from this. Always try to do an
aspiration with the patient in the proper position, bending
forward against a table, in full inspiration, and, if possible, with an
empty stomach. Investigations go hand in hand with clinical
inputs and with the patient status. Milk and chyle can have similar
physical characteristics and chemical composition, and
interpretation can depend on the feedback by the clinician to the
laboratory. Chylothorax is a debilitating and serious condition,
whereas transthoracic stomach aspiration is a technical error that
has no complications but can lead to a vexed clinical situation
that can confuse even the most experienced clinician. This was a
fantastic learning experience that has made us wiser and much
more sober.
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